secwatch.observer — SEC 8-K summary
======================================

Issuer:     Repare Therapeutics Inc. (—)
CIK:        0001808158
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001193125-25-068880
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Repare Therapeutics CEO Segal resigns; CFO Steve Forte becomes CEO effective April 11
--------------------------------------------------------------------------------

- Lloyd Segal resigns as President, CEO, and Director effective April 11, 2025; not due to disagreement.
- Steve Forte (current EVP/CFO) appointed President, CEO, and Director effective same date; will remain CFO.
- Sandra Alves promoted to SVP, Chief Accounting Officer; salary raised to CA$350,000; granted 24,500 options and 4,100 RSUs.
- Company expects to complete MYTHIC trial enrollment Q2 2025; topline data for POLAR (Q3) and LIONS (Q4) trials.
- Company exploring strategic alternatives and partnerships across portfolio, including for lunresertib and camonsertib.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808158/000119312525068880/0001193125-25-068880-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808158/000119312525068880/d923441d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-068880

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer